Investigational drug · Phase 3
Glucocorticoids
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
5 still active
All registered trials
786
Any phase or sponsor naming "Glucocorticoids"
First trial start
2022
Feb 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Glucocorticoids", any sponsor or status.
Conditions studied
As listed on its trial records.
- VEXAS Syndrome
- ANCA Associated Vasculitis (AAV)
- Anti-Glomerular Basement Membrane Disease
- Neuromyelitis Optica Spectrum Disorders
- ANCA-associated Vasculitis
- Myositis
Approved drugs for the same conditions: Immunology and inflammation · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Glucocorticoids" as an intervention, largest first.
AmgenAmgen (AMGN)
NCT02520362 · 517,991 participants · Start May 31, 2010 · Primary completion Jul 21, 2023
Drug: denosumab; bisphosphonate · For: Osteoporosis
University of LeedsAcademic, hospital or other
NCT03575247 · 111,804 participants · Start Jan 1, 1998 · Primary completion Jan 30, 2015
Drug: Glucocorticoids · For: Adrenal; Insufficiency Gluccorticoid-Induced; Cushing; Syndrome or Disease, Glucocorticoid-Induced
- The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory DiseasesCompleted
University of LeedsAcademic, hospital or other
NCT03760562 · 111,804 participants · Start Jan 1, 1998 · Primary completion Jan 30, 2015
Drug: Glucocorticoids · For: Hypertension
LEO PharmaIndustry
NCT03788863 · 99,999 participants · Start Nov 16, 2018 · Primary completion Nov 29, 2018
Drug: Diflucortolone valerate (BAY866146) · For: Relationship Between the Exposure of Glucocorticoids During Pregnancy and Orofacial Cleft Development
Sites: Multiple Locations, Germany
Prof Dr Frank ButtgereitAcademic, hospital or other
NCT02719314 · 10,000 participants (planned) · Start Dec 2015 · Primary completion Jul 2029
Drug: Glucocorticoid treatment · For: Osteoporosis; Inflammatory Rheumatism
Sites: Berlin, Germany
- The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19Pivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT05855395 · 5,815 participants (planned) · Start May 26, 2023 · Primary completion May 1, 2024
Drug: Glucocorticoid · For: COVID-19
Sites: Fuzhou, China; Quanzhou, China; Guangzhou, China · 15 sites in all
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 TrialPivotal-lookingRecruiting
Thomas EngstromAcademic, hospital or other
NCT07478003 · 5,204 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 20, 2031
Drug: Methylprednisolone 250 mg; NaCl (0,9%) · For: STEMI - ST Elevation Myocardial Infarction
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 4 sites in all
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)Pivotal-lookingStatus unknown
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyAcademic, hospital or other
NCT03390387 · 4,000 participants (planned) · Start Nov 2015 · Primary completion Nov 2020
Drug: Dexamethasone continuous; Dexamethasone intermittent and 8 more · For: Childhood Acute Lymphoblastic Leukemia
Sites: Yerevan, Armenia; Homyel, Belarus; Minsk, Belarus · 58 sites in all
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)Pivotal-lookingRecruiting
McMaster UniversityAcademic, hospital or other
NCT05114096 · 3,254 participants (planned) · Start Jul 20, 2023 · Primary completion Dec 31, 2026
Drug: Celestone + placebo; Celestone + Celestone · For: Preterm Birth; Premature Birth; Complication of Prematurity and 2 more
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 25 sites in all
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
Newest research
PubMed records naming it or its code names, newest first.
- Corticosteroid dose reporting in atraumatic osteonecrosis of the humeral head: a scoping review.
Ciavarro T, Elmaraghy A, Carroll PJ · JSES Rev Rep Tech 2027
- Fluorescence lifetime imaging of G-quadruplex RNA dynamics in Alzheimer's disease using a novel nucleic acid-sensitive probe.
Wang D, Huang W, Wang X, et al. · Talanta 2027
- Influence of glucocorticoid therapy, Cushing's syndrome and hypothyroidism on the reproductive cycle and AMH levels in the bitch.
Bauer E, Zablotski Y, Cremer J, et al. · Theriogenology 2027
- Psychoneuroimmunology of glioblastoma: How emotional states shape tumor biology.
de Melo MVG, Bezerra TPW, de Souza PC, et al. · Neuropharmacology 2027
- Sirolimus is associated with longer relapse-free survival than cyclosporine in autoimmune hemolytic anemia and evans syndrome: a retrospective cohort study.
Zhang Y, Wan J, Luo G, et al. · Autoimmunity 2026
- Microneedle-based drug delivery for inflammatory and immune-mediated ocular diseases: current applications and future perspectives.
Mi B, Jin F, Mu J, et al. · Drug Deliv 2026
Also in development for VEXAS Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.